Jardiance Storage, Stability & Shelf Life: Evidence-Based Handling Guide

The direct answer

Jardiance tablets should stay in their original, sealed blister packaging and be kept at normal indoor room temperature until the moment they are taken. The FDA-approved prescribing information for Jardiance specifies storage at 25°C (77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F), and instructs that the product be kept dry, according to the FDA-approved prescribing information. This is a labeling instruction, not a guarantee about every possible real-world condition, and the label does not publish stability data for tablets removed from their blister and placed in pill organizers, unlabeled bottles, or travel containers. A tablet that looks, smells, and feels normal and has been kept within these conditions can be used with ordinary confidence. A tablet that has been visibly wet, discolored, sticky, or crumbling should be discarded regardless of how much time is left before the printed expiration date, because the label's stability testing does not cover that condition.

Why storage is not just a housekeeping detail

Empagliflozin is approved for type 2 diabetes, and, at specific labeled doses, for heart failure with reduced or preserved ejection fraction and for chronic kidney disease, according to the FDA-approved prescribing information. These indications rest on large randomized outcome trials, including the pivotal cardiovascular outcomes trial in type 2 diabetes and the heart failure outcome trials that followed it. The exact magnitude of benefit reported in those trials is specific to the study populations and follow-up periods used, and readers who want precise effect sizes should consult the trial publications directly rather than a secondary summary; this page does not reproduce exact trial statistics because the original citation set behind this claim could not be independently verified against the primary literature at the time of this revision, and an unverifiable precise number is worse than an honest generalization.

The clinical point that matters for a storage discussion is simpler and does not depend on the exact trial numbers: these benefits assume the patient is actually receiving a full, intact dose. A tablet that has lost potency because of moisture damage delivers less active drug than the label assumes. Whether that loss is clinically meaningful for any individual patient is not something this page can quantify, but it is the reason storage guidance exists at all.

What the FDA label actually specifies

The Jardiance label lists 10 mg and 25 mg film-coated tablets, packaged in blister cards, and specifies storage at controlled room temperature with excursions to 15 to 30°C, according to the FDA-approved prescribing information. Tablets are meant to remain in the original blister until use. The label does not specify refrigeration, and it does not describe stability outside the original packaging. That silence is meaningful: it means neither the manufacturer nor the FDA has published data on how the tablet performs in a weekly pill organizer, a repackaged vial, or a travel case, so any such storage is being done without label-level assurance, even if it is common practice.

Pharmacy practice around beyond-use dating for repackaged products (for example, when a pharmacist splits a bulk bottle into smaller containers) is generally governed by United States Pharmacopeia general chapters on stability and storage practice. This article does not cite a specific USP chapter number here because the exact chapter language in the original draft could not be verified against the current USP-NF text; pharmacists should consult their current USP reference rather than relying on a citation from this page.

Shelf life and expiration: what the date does and does not mean

The FDA approval and stability testing standards that support Jardiance's expiration dating follow the general framework in FDA's stability testing guidance for new drug substances and products (FDA guidance, ICH Q1A(R2)). In broad terms, that framework requires manufacturers to test a drug product under long-term and accelerated conditions and to set an expiration date based on the point at which the product is expected to remain within specification. The expiration date printed on Jardiance packaging is the manufacturer's guarantee limit, not a cliff at which the tablet suddenly becomes unsafe.

Older research on other drug products stored well past their labeled expiration dates (for example, work associated with government shelf-life extension testing programs) has suggested that many solid oral products remain within specification for some period beyond the printed date under ideal storage. This article does not cite a specific percentage or number of months for that finding here because the exact study details in the original source could not be verified, and empagliflozin was not confirmed to be part of any such published extension analysis. The honest takeaway is that expiration dating is conservative by regulatory design, not that patients should use expired Jardiance. Continue to follow the printed date, and do not treat "probably still fine" science about other drugs as permission to use expired doses for a condition where consistent dosing matters, such as heart failure.

Temperature excursions: what is tolerated and what is not

Accelerated stability testing under the ICH framework typically exposes a drug product to elevated temperature and humidity (commonly 40°C and 75% relative humidity) for a defined period as part of establishing a shelf-life claim at normal room-temperature conditions (FDA guidance, ICH Q1A(R2)). This is a manufacturing and regulatory testing standard, not a patient-facing instruction to deliberately expose tablets to heat. The label's own excursion allowance (15 to 30°C) is narrower than the accelerated testing conditions and is the number patients and caregivers should actually use when judging a delivery or a warm room.

A package that arrives warm from summer shipping, while still sealed in its original blister, is a different risk than loose tablets that have been sitting in an open bottle in a humid bathroom. The label does not publish separate data comparing these two scenarios, so this page cannot tell a reader with certainty that a warm-but-sealed shipment is fine. What can be said plainly: intact, unopened blister packaging is the FDA-labeled condition the shelf life claim is built on, and any deviation from that (temperature, humidity, or removal from the blister) is a deviation from tested conditions, not a confirmed failure.

Moisture as the primary concern

The Jardiance label instructs that the product be protected from moisture, and the European Medicines Agency's public assessment report for Jardiance describes the drug substance as moisture-sensitive, noting that it should be protected from humidity during manufacture, packaging, and storage (EMA assessment report). That is a labeling and regulatory-document fact, not an independent laboratory finding by this page. The practical implication is straightforward: the sealed blister exists specifically to keep humidity away from the tablet, and removing tablets from that blister for extended periods (into a pill organizer, a plastic bag, or a bottle without desiccant) removes the protection the stability data was built around.

Visible signs that a tablet may have been compromised by moisture or heat include discoloration (yellowing or browning of the coating), an unusual odor, a sticky surface, or a tablet that crumbles when handled. None of these signs has been independently quantified by this page against a specific degradation threshold; they are general markers used across solid oral dosage forms to flag "do not take, ask the pharmacy for a replacement." Do not take a tablet showing these signs to "test" whether it still works.

How empagliflozin works, briefly

Empagliflozin inhibits SGLT2, a transporter in the kidney's proximal tubule responsible for reabsorbing most of the glucose filtered by the glomerulus. Blocking this transporter increases urinary glucose excretion and lowers blood glucose independent of insulin secretion. This mechanism is well established pharmacology and is described in empagliflozin's FDA-approved prescribing information. Specific numeric estimates of daily glucose excretion vary across sources and dosing conditions; a reader who needs an exact figure for a specific dose should check the current label or a pharmacology reference rather than relying on a single number repeated across web pages.

The reason mechanism matters for a storage article is dosing consistency. Empagliflozin's cardiovascular and renal effects in its approved indications are studied at labeled once-daily doses taken consistently over long follow-up periods. A degraded tablet delivering an uncertain, reduced dose is a deviation from that studied exposure. This page cannot state how much dose loss would be clinically meaningful, and no source provided supports a specific threshold, so the guidance stays qualitative: intact tablets stored as labeled, or discard and replace.

Combination products: Synjardy and Glyxambi

Empagliflozin is also marketed in fixed-dose combinations: Synjardy and Synjardy XR (empagliflozin with metformin) and Glyxambi (empagliflozin with linagliptin). Each of these products has its own FDA label and its own storage instructions, and readers should not assume Jardiance's instructions apply automatically, and should check the specific product's own FDA-approved labeling. Metformin is independently moisture-sensitive, which is a reason to be at least as careful, not less, about humidity exposure with Synjardy. Patients switching between empagliflozin-containing products should check the specific label rather than transferring assumptions from Jardiance.

Travel and hot climates

Airline cargo holds, hot cars, and humid climates without air conditioning are all situations that fall outside the FDA's tested storage range at some point. A parked car in direct sun can reach temperatures far above the labeled 15 to 30°C excursion range within a short time, so medication should not be left in a vehicle. For humid climates without reliable air conditioning, keeping tablets in their sealed blister inside a resealable bag with a desiccant packet is a reasonable, low-risk precaution, though it is not a labeled instruction and has not been independently tested for empagliflozin specifically in this article's source material.

Refrigeration (2 to 8°C) is not required or specifically recommended by the FDA label, but nothing in the label suggests that ordinary refrigerator temperatures would harm the tablets. Patients considering refrigeration as a workaround for a hot, humid home should treat it as a personal judgment call rather than a labeled instruction, and should still keep tablets in their original packaging inside the refrigerator.

For patients taking empagliflozin at heart failure doses, maintaining supply continuity is a clinical priority independent of storage conditions. Missing doses or running out of medication is a medication-adherence issue, not a storage issue, and patients concerned about gaps in heart failure therapy should contact their prescriber rather than relying on stored backup tablets of uncertain condition.

Storage decision framework: what to do with a questionable tablet or shipment

Use this sequence when a real-world storage question comes up. It does not replace label instructions, and it does not substitute for calling the dispensing pharmacy when in doubt.

What is established, what is plausible, and what is not established

Established: Jardiance's FDA label specifies room-temperature storage (25°C, with 15 to 30°C excursions permitted) and instructs that the product be protected from moisture and kept in its original packaging. The EMA assessment report independently identifies moisture as a sensitivity for the drug substance.

Plausible but not confirmed by the sources reviewed for this page: that brief, sealed-blister excursions above 30°C during shipping are clinically inconsequential; that refrigeration meaningfully improves stability in hot climates; that expired tablets retain clinically adequate potency for some period past the printed date. These are reasonable extrapolations from general pharmaceutical stability principles, not empagliflozin-specific data confirmed here.

Not established by the material available for this revision: specific quantitative degradation thresholds for empagliflozin under defined heat or humidity exposures, a validated beyond-use date for repackaged or organizer-stored tablets, and precise numeric effect sizes from the cardiovascular and heart failure outcome trials as they relate to storage-related dose loss. Readers who need those exact figures should consult the current FDA label directly or the primary trial publications, and a pharmacist or prescriber should be consulted for any situation involving a heart failure or chronic kidney disease indication where dosing consistency is more consequential.

When to seek urgent guidance: if a patient has missed multiple doses due to a supply or storage problem and is experiencing symptoms such as significant swelling, shortness of breath, or rapid weight gain, especially if they are being treated for heart failure, they should contact their prescriber or seek urgent care rather than waiting to resolve a storage question first.